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Abstract 
Cardiac and Mitochondrial Adaptations in Response to Aging and Doxorubicin in Rats Bred 
for Divergent Aerobic Capacities 
by Laura Larion 
July, 2012 
Director: Dr. Robert Lust 
DEPARTMENT OF BIOLOGY 
 
Doxorubicin (DOX) remains as one of the most widely prescribed and effective 
anticancer agents. A major limitation of the therapeutic effectiveness of the drug is the 
occurrence of irreversible, progressive, dose-dependent cardiotoxicity. Active aerobic 
running capacity has been shown to protect against DOX-induced cardiac dysfunction, but 
little is known of the protective effects of intrinsic non-trained aerobic capacity. We 
hypothesized that a low aerobic capacity running (LCR) phenotype will be more susceptible 
for cardiac mitochondrial dysfunction and decreased cardiac performance in response to 
doxorubicin stress, when compared to the high aerobic running capacity (HCR) animals. To 
test this hypothesis, cardiac function was assessed in rats specifically selected over 26 
generations for their low (LCR) and high (HCR) intrinsic aerobic running capacity. HCR/LCR 
rats received a single doxorubicin (7.5mg/kg of body weight) intraperitoneal injection and 
cardiac performance was studied longitudinally through echocardiography. On the tenth 
day, the animal was sacrificed, cardiac mitochondria were isolated and mitochondrial 
function was assessed through respirometry studies. Our results indicated that animals with 
low inherent aerobic capacity were susceptible to doxorubicin insult as evidenced by an 
adaptive mitochondrial response, while the high aerobic capacity animals appeared to have 
been physiologically primed and therefore did not exhibit an adaptive compensatory 
response.  
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CHAPTER I: INTRODUCTION 
Prevalence and Cost of Cancer 
Prevalence of Cancer  
 Cancer is one of the greatest public health concerns in the United States (Siegel et al., 
2012). According to the American Cancer Society, it is estimated that one in four United 
States residents will die due to cancer. In the year 2012, approximately 1.5 million new 
cancer cases and half a million deaths from cancer are projected to occur in the United 
States. Between genders, the lifetime probability of being diagnosed with an invasive cancer 
is higher for men (45%) than for women (38%). These statistics demonstrate that cancer is a 
prevalent cause of mortality and morbidity in the United States, and suggest that current 
therapies may not be effective at combating this illness. 
Cost of Cancer 
 Cancer accounts for a significant proportion of overall health care costs. The overall 
annual cost of cancer according to the National Institutes of Health in the United States in 
2010 was estimated to be about $260 billion (Scialdone et al., 2012). Direct medical costs 
accounted for $167.4 billion and lost productivity accounted for $119.2 billion (NHLBI, 2010). 
One study calculated that an individual’s treatment cost for the initial year after diagnosis 
can vary from $18,052 for a less invasive cancer to $42,401 for more advanced stages (Lang 
et al., 2009). The financial impact of cancer is not only costly for society, but also to the 
individual, as the direct and indirect costs of cancer to a patient can be devastating. 
Therefore, cancer’s burden on the nation is expensive (Ershler, 2003; Brown et al., 2001; 
Chang et al., 2004). 
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Cost-effectiveness Analysis of Chemotherapy 
 Due to its extensive incidence and high cost, improvement in the prevention, early 
detection and treatment of cancer is a major priority of medical research (Chang et al., 
2004). Current cancer treatment options include surgical intervention, radiation and anti-
tumor chemotherapy. Anticancer therapy aims to maximize the beneficial antitumor results 
while minimizing unwanted side effects and cost of treatment, to achieve the best outcome 
for the patient. Treatment evaluations of the cost of cancer care incorporate a large number 
of variables, making patient benefit-versus-cost management decisions difficult for 
oncologists and patients (Keefe et al., 2012). Despite their relative antitumor efficacy, a 
common patient survival value/benefit-versus-cost adjustment to chemotherapy treatment 
is attributed to the non-selective cytotoxicity side effects, such as myelosupression, nausea 
and vomiting, mouth ulcers and alopecia (Kizek et al., 2012). Serious adverse side effects 
force patients who may otherwise benefit from continued administration of a drug to 
withdraw from chemotherapy and switch to an alternative agent, which may be less 
effective (Swain et al., 2003).   
Doxorubicin-induced Cardiotoxicity 
Doxorubicin chemotherapy treatment 
 Toxic side effect limitations to chemotherapy is especially true for the anticancer 
agent doxorubicin (DOX, adriamycin), in this case due to its notorious cardiotoxic side effects 
(Greish, et al., 2004).  Since the drug’s discovery in 1969 from Steptomyces peucetius, a 
species of actinobacteria, it has been one of the most effective and prescribed antitumor 
clinical agents due to its wide spectrum of cytotoxicity (Arcamone et al., 1997;Simunek et al., 
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2009; Singal et al., 1997; Swain et al., 2003). The chemical structure consists of a tetracycline 
moiety containing a quinone and a conjugated amino sugar residue (Fig. 1) (Berthiaume et 
al., 2007). Doxorubicin is part of a group of anticancer drugs known as anthracyclines (ANTs) 
which are well established as successful antineoplastic antibiotics for various hemopoietic 
and solid malignancies, such as breast and esophageal carcinomas; osteosarcoma, Kaposi’s 
sarcoma and soft-tissue sarcomas; and Hodgkin’s and non-Hodgkin’s lymphomas (Bristow et 
al. , 1978; Hortobagyi  et al, 1997; Singal et al., 1998).  
 
 
Figure 1. The structure of Doxorubucin (Berthiaume et al., 2007) 
 
However, due to the drug’s small molecular size (543 Da), it lacks specificity to cancer 
cells and can be distributed to rapidly dividing cells, such as bone marrow and intestinal 
epithelial cells (acute toxicity) or more stable tissues, such as cardiac and hepatic tissues 
(chronic toxicity) (Greish et. al, 2004). Doxorubicin is known to accumulate preferentially in 
the heart creating a cardiotoxicity that causes organ dysfunction. This limits the 
administration of the drug to a cumulative dose exceeding ~500mg/m2 body surface area 
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(Singal et al, 1997). Thus, those with prior cardiac conditions are contraindicated from this 
medication, and precautions must be taken as the risk of cardiomyopathy is expected to 
increase in terms of severity and frequency in a linear dose-dependent manner (De Los 
Santos et al., 2000; Wondergem et al., 1991).  
Cardiotoxicity 
 Four types of anthracycline-induced cardiotoxicity have been recognized (Ferrans et 
al., 1997; Hrdina et al., 2000; Jones et al., 2006; Shan et al., 1996; Simunek et al. , 2009; 
Wouters et al., 2005). First, “acute” cardiotoxicity occurs immediately after administration 
and typically causes vasodilation, hypotension, and transient changes in cardiac rhythm 
(Ferrans et al., 1997). These disturbances usually reverted to normal and were mainly seen in 
adults (Hale et al., 1994). Second, “subchronic” or “subactute” cardiotoxicity manifests 1-3 
days after treatment as a pericarditis-myocarditis syndrome. This cardiotoxicity is 
uncommon and was particularly evident in the early trials of ANT treatment using very high 
doses in a short amount of time (Hale et al., 1994; Simunek et al., 2009). “Early chronic” is 
the third type of cardiotoxicity that develops weeks or months after the administration of 
the chemotherapy. It is characterized by dilated cardiomyopathy, left ventricular dysfunction 
and congestive heart failure (CHF) within a year after the completion of ANT therapy 
(Ferrans et al., 1997; Shan et al., 1996). Finally, “delayed” or “late-onset chronic” 
cardiotoxicity manifests years to decades after the completion of treatment, after a 
prolonged asymptomatic period. This latent toxicity was recognized at the start of the 1990s 
among adults who have survived pediatric cancers (Shan et al., 1996; Simunek et al., 2009). 
Patients with cardiomyopathy due to DOX-induced toxicity have an especially poor 
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prognosis, as their survival chances are worse than patients with ischemic cardiomyopathy 
(Felker et al., 2000). As the number of long-term cancer survivors continues to increase, 
chronic cardiotoxicity remains a clinically significant problem as the cardiac damage acquired 
after DOX-infusion is irreversible and progressively worsens.  
Several studies have attempted to explain the predilection of heart tissue to DOX-
toxicity. To begin with, the drug seems to be retained in cardiomyocytes more than in other 
cell types (Johnson et al., 1986). The exact pathogenesis of DOX-induced cardiotoxicity 
remains unclear although it is hypothesized that the drug exerts its antineoplastic and 
cardiotoxic action by distinct mechanisms: the anticancer response has been associated with 
lipid peroxidation, DNA intercalation, and inhibition of protein synthesis enzymes such as 
topoisomerase II (Arai et al., 2000; Arola et al., 2000; Billingham et al., 1978; Doroshow et al., 
1986; Greish et al., 2004; Muller et al, 1998; Myers et al., 1977; Singal et al., 1998; Wang et 
al, 2004). All of these effects result in cell cycle arrest that culminates in pro-apototic 
machinery leading to the death of cancer cells and tumor growth arrest (Pereira et al., 2011). 
There is increasing evidence that oxidative and pro-apoptotic stressors are the primary 
causal mechanisms responsible for the cardiotoxic activity (Lai et al, 2011; Ludke et al., 2011; 
Tokarska-Schlattner et al., 2006). Evidence suggests that the chemical structure of 
doxorubicin is prone to the generation of free radicals, leading to an increase in toxic 
reactive oxygen species (ROS) produced by the mitochondria, which trigger DNA damage and 
induces intrinsic mitochondria-dependent apoptotic pathways in cardiomyocytes (Koka et 
al., 2010; Mokni et al., 2012 Rajagopalan et al., 1988). Interestingly, this oxidative stress 
pathway has been found to be distinct from DOX-induced apoptosis induced in tumor cells 
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(Wang et al., 2004). This suggests that the principal cause of cardiac damage induced by the 
drug is through oxidative stress interaction with the myocardial mitochondria.  
 
 
Figure 2.  Equilibrium and loss of balance scenarios between oxidants (ROS) and antioxidants 
(AOX). Under normal conditions, there are sufficient antioxidants to overcome the ROS. A 
state of oxidative stress occurs when either ROS production is excessive or antioxidants are 
inadequate (Scandalios, 2002).  
 
Mitochondria and the Oxidative Stress Hypothesis  
Oxidative stress is the accumulation of reactive oxidative species beyond the capacity 
of antioxidants that damage important components inside the cell (Fig. 2) (Ago et al., 2010; 
Alexeyev, 2009). Oxidative stress is caused by free radicals or hydrogen peroxide derivatives 
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containing a free unpaired electron on its outer electron shell, thereby making them highly 
reactive and unstable (Cecarini et al, 2007). These molecules mutagenize proteins, lipids or 
nucleic acids and render them incapable of properly functioning. More specifically, oxidative 
stress is the difference between the concentration of oxidants necessary and beneficial for a 
cell in order for it to regulate physiological processes, and the uncontrolled oxidation caused 
by unregulated ROS production (Hole et al., 2011). Normally, an oxidative burst in 
conjunction with oxidative leakage from cellular respiration as well as with environmental 
factors causes the production of superoxide (O2). Superoxide dismutase (SOD) will convert 
the superoxide ions into hydrogen peroxide (H2O2), which will then be converted further into 
water and molecular oxygen by the enzyme catalase, reduced into water by glutathione 
peroxidase, or generate highly toxic hydroxyl radicals (OH) through catalytic transition 
metals, especially iron (Fe) (Fig. 3) (Simunek et al., 2009; Zhou and Kang, 2000). However, in 
situations of increased superoxide concentration, hydroxyl (OH) free radicals may form that 
are extremely reactive and cause protein and lipid peroxidation and DNA damage. The 
accumulation of cellular injury results in cell death (Ferrari, 1996). The primary generators of 
ROS in cells and tissues are mitochondria.  
  8 
 
 
Figure 3. Generation of ROS (modified from Shah, 2004). 
 
To meet the heart’s energetic demands, cardiomyocytes contain a very high 
mitochondrial content (30-40% of the cellular volume) relative to other organs (Yan et al., 
2008). The primary function of myocardial mitochondria is to generate ATP to support 
rhythmic contraction of the myocardium (Williamson, 1979). Through oxidative 
phosphorylation, the mitochondrial electron transport chains (ETCs) consume oxygen to 
convert into cellular energy in the form of ATP, which fuel cardiac contractile work (Stanley 
et al, 2004).  Although there are numerous endogenous producers of ROS, mitochondria 
continue to be significant sources of oxidant production. Mitochondria are the largest source 
of intracellular oxidant production in cardiomyocytes and approximately 1-2% of the 
electrons in the ETC leak to form superoxide anion, which is further converted into other 
ROS species (Anderson et al., 2011; Yan et al., 2008). Unfortunately, it is theorized that 
cardiac tissue has a less developed antioxidant defense system as catalase has not been 
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detected in the mitochondria except in rat myocardial cells (Nediani et al., 2011; Radi et al., 
1991). Since nearly 90% of ROS in cardiomyocytes can be traced back to the mitochondria, 
these organelles are a major source of ROS production and must maintain ROS at 
appropriate concentrations to prevent excess oxidation that, in turn, leads to further 
mitochondrial damage (Ago et al., 2010Balaban et al., 2005; Nicolson et al., 2008).  
In addition to being sources of oxidants, cardiac mitochondria are also uniquely 
susceptible to oxidative stress damage via doxorubicin (Johnson et al, 1986). Deleterious 
effects on mitochondrial bioenergetics are thought to be the primary targets of the drug’s 
cardiotoxicity (Chandran et al., 2009; Yen et al., 1996). After administration of doxorubicin in 
laboratory animals and humans, the generation of ROS and lipid peroxidation products 
increases while tissue antioxidant levels decrease (Conklin, 2005). Moreover, the amount of 
DOX-induced oxidants rises up to 10 times greater in the heart than it is in other tissues such 
as the liver, kidney and spleen (Conklin, 2005). The ability of doxorubicin to generate high 
levels of oxidative stress is due to the quinone moiety in its chemical structure. The drug has 
a high affinity for cardiolipin, a relatively cardiospecific negatively charged phospholipid that 
is found in the inner membrane of the mitochondria (Simunek et al., 2009; Wallace, 2003). 
Once inside the mitochondria, it can be reduced by the ETC into an unstable semiquinone. 
This radical intermediate is then oxidized, transferring an electron to oxygen to produce 
superoxide anion radicals that subsequently generate highly reactive hydrogen peroxide and 
other ROS (Esmat et al., 2012; Gilliam et al., 2012). This redox cycling behavior of doxorubicin 
initiates a cascade of free radicals which oxidize DNA bases, lipids, and proteins leading to a 
loss of cell integrity, enzyme function, and genomic stability (Esmat et al., 2012; 
  10 
 
Trachtenberg et al., 2011). As these unique modifications in the cardiac mitochondrial 
electron transport system can lead to cell death and ultimately organ damage, it is 
considered the primary mechanism underlying DOX-induced cardiotoxicity.  
Moreover, as the heart is a post-mitotic organ with low cardiomyocyte turnover rate 
(approximately 1% per year at age 20, declining to 0.4% per year at age 75), the oxidative 
damage will accumulate with time and the remaining undamaged cardiomyocytes cannot 
reconstitute the lost cardiac tissue, causing the heart to deteriorate functionally with time 
(Murry et al., 2009).  Therefore, due to the vital role that mitochondria play in cellular 
metabolism, dysfunction of this organelle as a result of doxorubicin-induced oxidative stress 
can have dire consequences. Dox-induced ROS may damage mitochondrial functions, such as 
oxidative phosphorylation, depressing myocardial ATP necessary for the energetic demands 
of the heart (Berthiaume et al., 2007). In order to protect the heart’s energy production 
machinery to allow for normal cardiac contractile performance, cardiac oxidants must be 
kept in balance.  Expanding our understanding of how to reduce reactive oxygen species 
overload will assist in preserving the integrity of the mitochondria in the face of oxidative 
stress and prevent fatal organ damage through cardiac toxicity.  
Prevention of DOX-Induced Cardiotoxicity 
Aerobic Capacity 
 As there is no effective treatment presently available for Dox-induced cardiotoxicity, 
prevention remains the best therapeutic. The aim of prevention is not only to prevent the 
toxicity, but also to increase the antitumor efficacy (Pereria et al., 2011). To circumvent the 
adverse side effects of doxorubicin, aerobic capacity and exercise have been suggested as 
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one of the few countermeasures to alleviate acute and chronic cardiotoxicity (Khakoo et al., 
2011). Maximal aerobic capacity is represented by the measure of maximal oxygen 
consumption (VO2max) typically by maximal treadmill running. The higher the VO2max, the 
greater the cardiovascular system has the ability to transport oxygen to the exercising 
muscles (Fitts et al., 1994). This is a standard tool that assesses the fitness of an individual 
and diverges with other cardiovascular dysfunction risk factors, such as cardiac energy 
substrate utilization, expression of key mitochondrial proteins, oxygen transport, and 
susceptibility to cardiac arrhythmias (Palpant et al., 2009) Studies have shown that exercise 
capacity is a strong predictor of early morbidity and mortality, and a clinical retrospective 
study demonstrated that low exercise capacity is a stronger predictor an increased risk of 
death than other established risk factors, such as hypertension, diabetes, or smoking (Koch 
et al., 2011; Myers et al., 2002). Thus, aerobic capacity is implicated in both an immediate 
functional performance perspective and from a prospective survival outlook (Rognmo et al., 
2004).  
Exercise preconditioning attenuates DOX-induced oxidative stress 
 Aerobic exercise capacity can be divided into (i) adaptational (as a response to active 
exercise training) or (ii) intrinsic (untrained) phenotypic profiles (Koch et al., 2008). Studies 
have shown that the first type of aerobic exercise, which includes walking, running, 
treadmill, cycling and calisthenics, causes weight loss, decreased insulin resistance, increased 
aerobic capacity, decreased lipids, decreased systolic blood pressure and decreased 
inflammation (C-reactive protein) (Moinuddin et al., 2012). The benefits of aerobic exercise 
training are well established as regular exercise has been shown to reduce the risk of heart 
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disease, control hypertension and protect the heart against oxidative stress and apoptosis 
(Wonders et al., 2008). Moreover, exercise has been shown to reduce arrhythmia, decrease 
myocardial stunning, and improve vascular reactivity in hearts exposed to ischemia-
reperfusion (Frasier et al., 2011). In regards to doxorubicin-induced toxicity, there are 
various exercise training regimens - acute vs. chronic (repeated) - that have shown that 
exercise preserved cardiac function in mice receiving the drug (Jones et al., 2010). More 
specifically, exercise alleviates doxorubicin toxicity by improving antioxidant status, 
attenuating apoptotic pathways, and preserving contractile function expression. It is 
theorized that exercise training induces increases in catalase and glutathione peroxidase 
activities which are beneficial under elevated ROS conditions, such as when induced by DOX 
as the drug has been shown to induce additional ROS production in mitochondria and 
increase oxygen consumption by a factor of six (Ascensao et al., 2005; Martins et al., 2012). 
Thus, exercise may confer a protective preconditioning effect against DOX-induced ROS 
generation.  
Intrinsic aerobic capacity  
There is plenty of evidence indicating that regular physical activity can aid in the 
prevention and treatment of a wide assortment of cardiovascular ailments and is a 
significant, modifiable behavioral risk factor (Armstrong et al., 2006). However, not everyone 
is physically able to exercise, and in some cases, hospitalization for immune complications 
associated with either the cancer or its treatment may preclude exercise.  In either case, the 
role of the latent capacity for aerobic exercise in the overall response is not clear, but 
certainly important.  However, much less is known about how intrinsic aerobic capacity, 
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independent from active exercise, plays a role in predicting cardiovascular fitness. Twin and 
family studies have supported the heritability of intrinsic aerobic capacity as both the ability 
to perform and the propensity to engage in exercise (Waters et al., 2008). The HERITAGE 
Family investigated the genetic contribution to the untrained fitness level as well the 
potential of training-induced improvements (Blouchard, 2012). They explored the 
adaptational response to exercise by engaging 742 healthy but sedentary subjects in a highly 
standardized, well-controlled endurance-training protocol for 20 weeks and recorded the 
VO2max response. They observed that the varied response that some individuals were highly 
trainable while others had little or no benefit to training. The heritability was determined to 
be 47% for the VO2max response, with a maternal transmission of 28%. Also, there was a 
reported 2.5 times more variance between families than within families. This raised the 
possibility that mitochondrial DNA is involved in heterogeneous response to training and 
that there is a significant genetic basis to exercise (Bouchard et al., 1999).  
HCR/LCR animal model  
To further study the genetic contribution of aerobic capacity, Koch and Britton 
developed two strains of rats with marked differences in intrinsic aerobic exercise capacity 
phenotypes (Koch et al., 2001). This was accomplished by two-way artificial selective 
breeding of rats that exhibited either high capacity (HCR) or low capacity (LCR) endurance 
treadmill running capacity. In 1996, the research group initiated a breeding project 
consisting of 96 male and 96 female rats using the genetically heterogeneous rat population 
from N:NIH (National Institutes of Health) stock as the founder population. At 11 weeks of 
age, running capacity was assessed by using an incremental velocity treadmill running 
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protocol. Intentional crossbreeding of 13 lowest- and 13 highest-capacity rats of each sex 
were selected and randomly paired for mating. Genetic variance among the population was 
maximized by not selecting among brothers and sisters. After 11 generations of selection, 
the LCR and HCR rats differed by 347% in aerobic running capacity. In 2007, 21 generations 
of selection had been performed and there was a 461% divergence in running capacity. The 
difference in VO2max was due largely as a consequence of changes in the capacity to deliver 
oxygen to the exercising muscle; HCR rats had a greater maximal cardiac output (Koch et al., 
2008). This divergent animal model yields rats that can be studied without potentially 
confounding additional environmental adaptations that occur with exercise training (Lessard 
et al., 2009).  
 Current results suggest that HCR/LCR rats can serve as genetic models that contrast 
for disease risks and indirectly support a mechanistic role for oxygen metabolism (Koch et al., 
2008). Thus far, many studies have observed divergent characteristics between these model 
organisms. LCR rats have accumulated cardiovascular risk factors, such as a large gain in 
visceral adiposity, hypertension, dyslipidemia, impaired glucose tolerance, endothelial 
dysfunction, hyperglycemia, hypertriglyceridemia, insulin resistance and elevated plasma 
free fatty acids (Koch et al., 2011; Wisloff et al., 2005). In addition, LCR rats have decreased 
stroke volume, reduced systolic and diastolic cardiac function, as well as impaired oxygen 
supply extraction ratio and tissue diffusion capacity in skeletal muscle as compared to HCR 
rats (Hoydal et al., 2007). Moreover, LCR rats expressed decreased levels of proteins involved 
in mitochondrial function in skeletal muscle, supporting the notion that impaired regulation 
of oxidative pathways in mitochondria may be a linkage between aerobic capacity and 
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cardiovascular disease (Wisloff et al., 2005). In summary, LCR rats score high on disease risks 
associated to the metabolic syndrome, which is defined as collection of symptoms that may 
predispose for cardiovascular disease, and HCR rats score high for health factors related to 
maximal oxygen consumption (Koch et al., 2008). LCR rats also respond more negatively to 
environmental health risks, such as high fat diets (Noland et al., 2007). Therefore, it would be 
worthwhile to examine how this aerobic rat models respond differentially to doxorubicin-
induced cardiotoxicity.  
Goal of Current Study 
 Based on previous studies of diverging susceptibilities for cardiovascular risk factors 
between LCR and HCR rats, we hypothesized that indexes of cardiac function after 
doxorubicin administration (stressor) would co-segregate with intrinsic aerobic capacity. We 
hypothesize that the rats will exhibit differential responsiveness to doxorubicin-induced 
cardiotoxicity.  
 We hypothesize that an attenuated aerobic capacity as found in LCR rats has a 
genetic profile that is deficient in their antioxidant defenses and mitochondrial functions. 
Therefore, with a diminished ability to metabolize and detoxify oxygen, they are left more 
susceptible to the oxidant burden of doxorubicin.  
 Therefore, the aim of this thesis was to study the influence of intrinsic aerobic 
exercise capacity on metabolic and cardiac adaptive responses to doxorubicin-induced 
toxicity, and tests the overall hypothesis that the low aerobic endurance running capacity 
(LCR) phenotype will show altered metabolic and cardiac responses to doxorubicin when 
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compared to the high aerobic endurance running capacity (HCR) phenotype. Moreover, we 
expect that the HCR phenotype confers cardioprotection against doxorubicin-induced 
cardiotoxicity as compared to the LCR phenotype.  
CHAPTER II: METHODS 
 
Animal Care 
 Female HCR/LCR rats were obtained from Drs. Lauren Koch and Steven Britton at the 
University of Michigan (aged approximately 25 months) and obtained from generation 26.  
The creation of the HCR/LCR rat model has been previously described in detail (Britton, 
2005; Koch et al., 2001; Koch et al., 2008). All animals were housed 2 per cage in a 
temperature-controlled 12/12-hour light/dark cycle facility, where standard rat chow and 
water were provided ad libitum.  Rats were randomly assigned into four groups: LCR injected 
with saline, (LCR + SAL) (n=6), LCR injected with DOX (LCR + DOX) (n=9), HCR injected with 
saline (HCR + SAL) (n=3) and HCR injected with DOX (HCR+DOX) (n=5). The number of rats in 
the LCR + DOX and HCR + DOX groups was greater to accommodate the potential mortality 
following DOX. All protocols were approved by the Brody School of Medicine at East Carolina 
University Institutional Animal Care and Use Committee and were in compliance with Animal 
Welfare Act guidelines. 
 
Doxorubicin Administration 
The LCR + DOX and HCR + DOX groups received a single intraperitoneal DOX injection 
(7.5mg/kg of body weight), while the control groups received an injection of 0.9% sterile 
saline at equivalent volumes.  
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Figure 4: Schematic representation of the experimental schedule used for assessing the 
Doxorubicin-induced cardiotoxicity in the rat. Solid arrows denote body weight 
measurements and ultrasounds. i.p., intraperitoneal.  
 
Assessment of Cardiac Function 
 
Transthoracic echocardiography was conducted on sedated rats using a commercially 
available echocardiographic system (Vevo 2100, Visual Sonics Inc., Toronto, Ontario, Canada) 
with a 13-24 MHz linear array transducer (MS250). Echocardiogram and body weight 
measurements were made prior to injection (baseline) and 1, 4, 7 and 10 days post-injection 
(fig.1). Rats were anesthetized by isoflurane (2-2.5%) delivered through a nose cone and the 
echocardiography was completed within 15 minutes after the administration of the sedative. 
The hair on the thoracic area was removed by applying a depilatory. Ultrasound transonic 
blue gel was placed on the thorax to optimize visibility. Two-dimensional images of the left 
ventricle were obtained in the parasternal long-axis and short-axis views. B and M-mode 
images were obtained at the midventricular level in both views, from which internal 
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dimensions of the left ventricle were obtained at end diastole and end systole (Figures 5 and 
6). All images were analyzed using Vevo 2100 1.3.0 software (Visual Sonics Inc.).  
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Isolated Rat Heart 
Rats were anesthetized using 90mg/mL ketamine and 10mg/mL xylazine, dosed at 0.1 
mL/100g body weight. Once animal sensation reflexes, including eye blink, pedal and tail 
pinch reflexes were absent, the heart was rapidly harvested by midline thoracotomy and 
placed in ice-cold mitochondrial isolation medium (MIM) buffer for myocardial 
mitochondrial isolation.  
Myocardial Mitochondrial Isolation 
Mitochondria were isolated from the LV using a modified protocol (Boehm et al., 
2001). From the excised heart, LV was removed, minced, and digested in 10mLs of MIM 
buffer (300 mmol/L sucrose, 10mmol/L Na-HEPES, and 0.2mmol/L EDTA, pH 7.2) containing 
125mg/mL trypsin for 2 minutes and then diluted with trypsin inhibitor medium (10mL of 
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MIM, pH 7.4, 1mg/mL BSA, and 165mg/mL trypsin inhibitor).  The partially digested muscle 
was suspended in 10mL of MIM containing 1mg/mL BSA and homogenized briefly using a 
Potter-Elvehjem homogenizer. By differential centrifugation (once at 600 g (4°C) for 10 
minutes and twice at 8000 g (4°C) for 30 minutes, a mitochondrial fraction was obtained as a 
protein pellet.. The final mitochondrial pellet was suspended in 200uLs of MIM and protein 
quantification was determined using a Pierce BCA kit.  
Mitochondrial Respiration 
 The respiratory rates of isolated cardiac mitochondria (100 ug) were measured at 
25°C in an Oroboros oxygraph in mitochondrial respiration medium (MiR05) (Oroboros 
Oxygraph-2K, Oroboros Instruments Corp., Innsbruck, Austria). To prevent oxygen limitation, 
the respiration chambers were hyperoxygenated up to ~400 umol/l O2. Once oxygen 
concentration flux stabilized, substrates were added as described in Table 1 and Table 2. The 
stable portion of the oxygen concentration slope was determined for each addition in both 
protocols and normalized as in previous respiration studies (Boyle et al., 2011, Anderson et 
al., 2009).  
 
Table 1. Respirometry protocol A.  
Step Substrate Notation Concentration 
1 Mitochondria Mito 100ug 
2 Glutamate  
Malate 
G 
M 
5 mM 
2 mM 
3 ADP ADP 2 mM 
4 Succinate Succ 5 mM 
5 Rotenone Rot 10 uM 
6 FCCP FCCP 0.75 uM 
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Protocol A consisted of the following substrate additions: (i) 5 mM glutamate (complex I 
substrate) + 2 mM malate (complex I substrate), (ii) 2 mM ADP (state 3 condition), (iii) 5 mM 
succinate (complex II substrate), (iv) 10μM rotenone (inhibitor of complex I), and (v) 0.75 μM 
carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP, a protonophoric uncoupler).  
 
Table 2. Respirometry protocol B.  
Step Substrate Notation Concentration 
1 Mitochondria Mito 100ug 
2 Palmitoyl carnitine 
Malate 
PC 
M 
25 mM 
2 uM 
3 ADP ADP 2 mM 
4 Glutamate Glu 5 mM 
5 Succinate Succ 5 mM 
6 FCCP FCCP 0.75 uM 
PC, M: PCM4 
PC, M, ADP: PCM3 
 
Protocol B consisted of (i) 25 mM palmitoyl carnitine (fatty acid substrate) + 2 μM 
malate, (ii) 2 mM ADP, (iii) 5 mM glutamate, (iv) 5 mM succinate, and (v) 0.75 μM FCCP. 
Specific substrate additions allowed for measurement of state 4 (substrate only, no ADP 
added), state 3 (ADP), and chemically uncoupled (FCCP) respiration rates. Protocol B 
observed respiration supported exclusively by lipid (PC) under state 4 (PCM4) and state 3 
(PCM3). The rate of mitochondrial O2 consumption was expressed as picomoles per second 
per mg of protein. The respiratory control ratio (RCR) was set as the ratio of oxygen 
consumption at state 3 over oxygen consumption at state 4. 
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Statistical analyses 
 Statistical analyses were performed using commercial software (Prism Software, 
Irvine, CA) on raw or log-transformed data. For HCR/LCR animal characteristics, t-tests were 
performed.  Analysis of variance with repeated measures was used to compare changes in 
any echocardiographic parameter over time.  Similarly, analysis of variance was used to 
compare substrate responses in respirometry protocols.  Analysis of variance also was used 
to compare differences between groups at any given time.  Specifically, the following 
comparisons were considered: LCR control vs. HCR Control, LCR Control vs. LCR + DOX, HCR 
Control vs. DOX, and LCR + DOX vs. HCR + DOX.  The following comparisons were considered 
biologically irrelevant, and were excluded from statistical comparison; LCR Control vs. HCR + 
DOX, HCR Control vs. LCR + DOX.   In each case, data are presented as the mean ± S.E.M. 
Statistical significance was accepted when p < 0.05. 
CHAPTER III: RESULTS 
 
Phenotype Characteristics 
 
 Animals were characterized as either Low Aerobic Capacity (LCR) running rats, or High 
Aerobic Capacity (HCR) Running Rats, based on responses to a graded, progressive exercise 
test.   Each rat was run on a motorized treadmill set at 10 m/min on a 15-degree slope, with 
programmed increases in speed (1 m/min, every 2 min) until the animals reached 
exhaustion. Rats were tested daily over 5 consecutive days, and the greatest distance run in 
meters out of the five trials was considered the best estimate of intrinsic exercise capacity.   
A summary of the demographic data is provided in Table 3.   
HCRs had significantly lower body weights (211 ± 3 vs. 158 ± 2 grams, mean ± SEM, 
LCR vs. HCR, p < 0.0000) (figure 7),   HCR animals also ran more than 400% longer (78 ± 1 vs. 
19 ± 0 minutes,  mean ± SEM,  HCR vs. LCR, p < 0.0000) (figure 8), more than 8 times farther 
(2276 ± 43 vs. 274 ± 7 meters, mean ± SEM,  HCR vs. LCR, p < 0.0000) (Figure 9), and 
achieved running speeds 260% faster (49 ± 1 vs. 19 ± 0 meters, mean ± SEM,  LCR vs. HCR, p 
< 0.0000) (Figure 10).  Consistent with the possibility that at least some of the running 
capacity has more to do with behavioral elements, than physiological capacity, LCR animals 
were significantly less likely to improve with repeated trials.  32% of LCRs vs. only 8% of HCRs 
(p < 0.001, Chi-Square) in this cohort had their best performance on the first trial, while 92% 
of HCRs had their best performances on the last trial, against only 35% of LCRs (p < 0.001, 
Chi-Square). These data are summarized in (Figure 11) 
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TABLE 3.   Summary of individual BWs and best performances at the time of phenotyping. 
 
    LCRs       HCRs   
 
Body wt Time Distance Speed Body wt Time Distance Speed 
 
(g) (min) (m) (m/min) (g) (min) (m) (m/min) 
 
204 21 317 20 149 71 1931 45 
 
215 18 250 18 139 71 1949 45 
 
236 14 178 16 156 72 1960 45 
 
210 18 249 18 154 72 1990 46 
 
182 14 177 16 189 72 1997 46 
 
202 20 294 20 172 73 2009 46 
 
188 20 293 20 148 74 2050 46 
 
238 22 339 21 160 74 2050 46 
 
217 18 257 19 172 74 2061 46 
 
203 20 290 20 168 74 2067 46 
 
218 16 210 17 139 74 2067 46 
 
261 17 239 18 150 74 2081 47 
 
197 20 283 19 172 75 2113 47 
 
198 20 295 20 154 75 2116 47 
 
220 18 255 19 163 75 2129 47 
 
219 20 288 19 178 76 2154 47 
 
218 18 246 18 157 76 2184 48 
 
203 15 203 17 174 76 2187 48 
 
227 21 305 20 161 77 2218 48 
 
198 19 263 19 146 78 2274 49 
 
200 21 316 20 157 79 2312 49 
 
216 20 300 20 148 80 2342 49 
 
196 21 308 20 141 80 2353 49 
 
225 19 279 19 157 80 2363 50 
 
214 20 282 19 168 80 2369 50 
 
208 21 303 20 155 81 2405 50 
 
214 21 304 20 173 81 2412 50 
 
195 22 334 21 165 82 2463 51 
 
177 17 240 18 157 82 2477 51 
 
208 21 307 20 161 82 2481 51 
 
203 18 244 18 156 84 2558 51 
 
248 19 278 19 157 85 2595 52 
 
197 17 240 18 147 87 2704 53 
 
193 21 314 20 140 88 2796 54 
 
210 20 291 20 161 89 2822 54 
  243 20 297 20 143 90 2884 55 
mean 211 19 274 19 158 78 2276 49 
SEM 3 0 7 0 2 1 43 0 
p  0.0000 0.0000 0.0000 0.0000   
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Figure 7.  Summary of body weight differences between HCR and LCR cohorts at the time of 
phenotyping (12 weeks of age).  * indicates p< 0.05 vs. HCR 
 
Figure 8.  Summary of best run times in the HCR and LCR cohorts at the time of phenotyping 
(12 weeks of age).  * indicates p< 0.05 vs. HCR 
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Figure 9.  Summary of best run distances HCR and LCR cohorts at the time of phenotyping 
(12 weeks of age).  * indicates p< 0.05 vs. HCR 
 
 
Figure 10.  Summary of best run speeds in HCR and LCR cohorts at the time of phenotyping 
(12 weeks of age).  * indicates p< 0.05 vs. HCR 
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Figure 11.  Summary of best performance trial (1-5) in the HCR and LCR cohorts at the time 
of phenotyping (12 weeks of age).  * indicates p< 0.05 vs. HCR 
 
 
Echocardiographic Assessment  
 
Control Comparisons 
 
 In general, there were no statistical differences overall under control conditions 
between HCR and LCR animals.   HCR animals tended to operate with higher end diastolic 
volumes (Table 4, Figure 12), end systolic volumes (Table 5, Figure 13), stroke volumes (Table 
6, Figure 14) cardiac outputs (Table 7, Figure 15) and heart rates (Table 8, Figure 16).    The 
picture is consistent with an increased overall hyperdynamic hemodynamic state, but also 
with a picture that no one variable in cardiac performance can explain the differences in 
performance in aerobic performance.  The ejection fractions (Table 9, Figure 18), were 
essentially identical between groups, and therefore, a significant difference in intrinsic 
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cardiac contractility likely does not explain the overall difference in performance.   However, 
it is possible that the present results simply represent the residual vestige effects of a larger 
difference that may have been present at earlier ages. 
 
TABLE 4.  Summary of left ventricular end-diastolic volume (LVEDV) changes by phenotype. 
 
 
    LVEDV (uL)     
 day 0 day 1 day 4 day 7  day 10 
HCR 162 185 216 199 212 
Control 223 233 233 284 305 
  315 268 321 371 223 
mean 233 229 257 285 247 
SEM 36 20 27 40 24 
p vs day 0   0.4236 0.1050 0.1719 0.2799 
      
LCR 209 245 176 98 223 
Control 173 153 168 311 307 
 
247 264 300 275 202 
 
271 205 279 238 199 
 
161 114 171 182 208 
  168 168 171 175 204 
mean 205 162 207 198 204 
SEM 19 22 29 16 2 
p vs day 0 
 
0.2175 0.1960 0.4677 0.3597 
p vs HCR 0.2493 0.1779 0.1559 0.1229 0.2473 
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Figure 12.  Summary of diastolic ventricular chamber size by phenotype. 
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TABLE 5.  Summary of left ventricular end systolic volume (LVESV) changes by phenotype. 
 
 
    LVESV (uL)     
 day 0 day 1 day 4 day 7  day 10 
HCR 49 51 56 55 48 
Control 66 73 75 83 79 
  95 89 88 97 58 
mean 70 71 73 78 62 
SEM 11 9 8 10 7 
p vs day 0   0.4082 0.1838 0.1177 0.1376 
      
LCR 71 44 49 32 71 
Control 42 33 43 107 93 
 
71 90 96 86 79 
 
94 45 68 68 42 
 
36 37 39 46 50 
  36 36 29 39 50 
mean 58 39 45 51 47 
SEM 10 2 10 7 2 
p vs day 0 
 
0.1592 0.0842 0.2393 0.4523 
p vs HCR 0.2540 0.0764 0.1335 0.2268 0.4283 
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Figure 13.   Summary of systolic chamber size by phenotype. 
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TABLE 6.  Summary of left ventricular stroke volume (LV SV) changes by phenotype. 
 
 
    LV SV (uL)     
 day 0 day 1 day 4 day 7  day 10 
HCR 113 134 160 144 164 
Control 157 160 158 201 226 
  220 179 233 274 165 
mean 163 158 184 206 185 
SEM 25 11 20 31 17 
p vs day 0   0.3933 0.1244 0.1837 0.3365 
      
LCR 138 201 127 66 152 
Control 131 120 125 204 214 
 
176 174 204 189 123 
 
178 160 211 170 157 
 
125 77 132 136 158 
  132 132 142 136 154 
mean 145 123 161 147 156 
SEM 14 20 20 9 1 
p vs day 0 
 
0.4337 0.2682 0.3806 0.3304 
p vs HCR 0.2593 0.3170 0.1875 0.0943 0.1481 
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Figure 14.  Summary of left ventricular stroke volume (LV SV) changes by phenotype. 
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TABLE 7.  Summary of heart rate (Rate) changes by phenotype. 
 
 
 
    Rate (bpm)   
 day 0 day 1 day 4 day 7  day 10 
HCR 325 365 335 362 269 
Control 341 315 343 347 348 
  318 326 316 337 302 
mean 328 335 331 349 306 
SEM 6 12 7 6 19 
p vs day 0   0.3687 0.4180 0.0641 0.1311 
      
LCR 345 250 356 359 348 
Control 345 334 323 316 313 
 
387 402 368 371 336 
 
270 340 372 338 310 
 
336 300 328 336 312 
  330 342 345 312 319 
mean 312 327 348 329 314 
SEM 17 11 10 7 2 
p vs day 0 
 
0.3769 0.1723 0.1252 0.0313 
p vs HCR 0.3771 0.4119 0.1160 0.2585 0.1879 
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Figure 15.   Summary of heart rate (Rate) changes by phenotype.  * p < 0.05 vs. day zero 
value.  
 
  37 
 
TABLE 8.  Summary of left ventricular cardiac output (CO) changes by phenotype. 
 
 
    CO (ul/min/g)     
 day 0 day 1 day 4 day 7  day 10 
HCR 123 165 146 192 162 
Control 198 162 166 203 244 
  176 170 149 146 144 
mean 166 166 154 180 183 
SEM 18 2 5 14 25 
p vs day 0   0.5000 0.1366 0.1093 0.4489 
      
LCR 91 116 106 72 122 
Control 128 97 100 147 156 
 
157 162 175 167 100 
 
104 137 178 130 109 
 
147 51 134 145 157 
  174 182 161 141 197 
mean 142 123 158 139 154 
SEM 17 31 10 4 21 
p vs day 0 
 
0.3265 0.1485 0.2803 0.3714 
p vs HCR 0.1109 0.0923 0.3020 0.0386 0.0948 
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Figure 16.   Summary of left ventricular cardiac output (CO) changes by phenotype.   
$ p < 0.05 vs. HCR value at the same time point. 
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TABLE 9.  Summary of left ventricular ejection fraction (LV EF) changes by phenotype. 
 
 
    LV EF (%)     
 day 0 day 1 day 4 day 7  day 10 
HCR 70 72 74 72 77 
Control 70 69 68 71 74 
  70 67 73 74 74 
mean 70 69 71 72 75 
SEM 0 1 2 1 1 
p vs day 0   0.3619 0.1875 0.3063 0.0923 
      
LCR 66 82 72 67 68 
Control 76 78 74 66 70 
 
71 66 68 69 61 
 
65 78 76 71 79 
 
78 68 77 75 76 
  79 79 83 78 75 
mean 74 75 79 75 77 
SEM 3 3 2 1 1 
p vs day 0 
 
0.2740 0.4951 0.0124 0.3993 
p vs HCR 0.2523 0.1011 0.1562 0.3180 0.1979 
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Figure 17.  Summary of left ventricular ejection fraction (LV EF) changes by phenotype. 
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Phenotypic responses to Doxorubicin  
 Doxorubicin treatment had no real effect on end-diastolic volume in the HCR animals, 
but end-diastolic volume increased significantly in the LCR animals (Table 10, Figures 18, 19).     
Similarly, end systolic volumes in the left ventricle also tended to increase significantly in the 
LCR animals, but not in the HCRs (Table 11, Figures 20, 21).  The data are consistent with a 
mild loss of function in the LCR animals in the first 4-7 days. 
TABLE 10.  Summary of left ventricular end-diastolic volume (LVEDV) changes caused by 
doxorubicin treatment in each phenotype.  
 
    LVEDV (uL)     
  day 0 day 1 day 4 day 7  day 10 
HCR + Dox 106 226 240 143 288 
 
252 187 247 250 204 
 
187 238 191 199 240 
 
335 238 392 250 399 
  110 210 197 243 113 
mean 198 220 253 217 249 
SEM 44 10 36 21 47 
p vs day 0 
 
0.3215 0.1946 0.1813 0.2946 
p vs HCR 0.0804 0.1396 0.4600 0.1340 0.4870 
      
LCR + Dox 223 231 307 213 275 
 
178 163 301 110 194 
 
279 279 290 252 339 
 
250 301 325 315 329 
 
205 212 236 214 277 
 
187 153 259 243 169 
 
197 216 178 268 175 
 208 225 197 191 225 
mean 216 223 262 226 248 
SEM 12 18 19 21 24 
p vs day 0 
 
0.2394 0.0599 0.1241 0.1995 
p vs LCR  0.3654 0.0000 0.0000 0.0000 0.0000 
p vs. HCR D  0.3177 0.4566 0.4145 0.3943 0.4924 
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Figure 18.  Summary of left ventricular end-diastolic volume (LVEDV) changes caused by 
doxorubicin treatment in each phenotype. 
 
 
Figure 19.  Summary of Doxorubicin effect compared to control in each phenotype.   
* p < 0.05 vs. control value at each time point.  
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TABLE 11.  Summary of left ventricular end-systolic volume (LVESV) changes caused by 
doxorubicin treatment in each phenotype.  
 
 
    LVESV (uL)     
  day 0 day 1 day 4 day 7  day 10 
HCR + Dox 32 74 71 51 104 
 
62 86 83 109 57 
 
91 83 79 52 96 
 
155 92 202 111 212 
  29 87 59 88 39 
mean 74 84 99 82 102 
SEM 23 3 26 13 30 
p vs day 0 
 
0.3230 0.2932 0.2449 0.2774 
p vs HCR 0.4215 0.0539 0.0510 0.1490 0.0537 
      
LCR + Dox 33 75 78 39 36 
 
50 37 110 29 69 
 
20 64 68 107 115 
 
27 76 76 104 123 
 
51 49 64 59 94 
 
55 48 52 67 49 
 
36 33 72 52 37 
 36 81 47 20 40 
mean 38 58 71 60 70 
SEM 4 7 7 11 13 
p vs day 0 
 
0.0437 0.1402 0.2218 0.1016 
p vs LCR 0.0161 0.4808 0.0702 0.4143 0.1102 
p vs. HCR D  0.0429 0.0058 0.1143 0.1155 0.1468 
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Figure 20.  Summary of left ventricular end-systolic volume (LVESV) changes caused by 
doxorubicin treatment in each phenotype.     $ p < 0.05 vs. HCR phenotype at the same time 
point. 
 
 
Figure 21.    Summary of Doxorubicin effect compared to control on left ventricular end-
systolic volume (LVESV) in each phenotype. * p < 0.05 vs. control value at each time point.  
$ p < 0.05 vs. HCR phenotype at the same time point.  
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Doxorubicin treatment was associated with a decreasing stroke volume in the HCR animals, 
while stroke volume tended to increase in the LCRS, consistent with the increased overall 
volumes observed in these animals (Table 12, Figures 22, 23).  The changes were seen 
variably over the entire 10 day observation period, consistent with a system under stress.    
TABLE 12. Summary of left ventricular stroke volume (LV SV) changes caused by doxorubicin 
treatment in each phenotype.  
 
    LV SV (uL)     
  day 0 day 1 day 4 day 7  day 10 
HCR + DOX 74 152 169 92 184 
 
190 101 164 141 147 
 
96 155 112 147 144 
 
180 146 190 139 187 
  81 123 138 155 74 
mean 124 135 155 135 147 
SEM 25 10 13 11 20 
p vs day 0 
 
0.3690 0.1722 0.1970 0.3446 
p vs HCR 0.0167 0.0228 0.1277 0.0220 0.0863 
      
LCR + DOX 190 156 229 174 239 
 
128 126 191 81 125 
 
259 215 222 145 224 
 
223 225 249 211 206 
 
154 163 172 155 183 
 
132 105 207 176 120 
 
161 183 106 216 138 
 173 144 150 171 185 
mean 177 165 191 166 178 
SEM 16 15 17 15 16 
p vs day 0 
 
0.0834 0.1105 0.1666 0.2903 
p vs LCR 0.0469 0.1883 0.0072 0.1639 0.0468 
p vs. HCR D  0.0424 0.0906 0.0773 0.0821 0.1337 
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Figure 22.   Summary of left ventricular end-systolic volume (LVESV) changes caused by 
doxorubicin treatment in each phenotype.      
 
Figure 23.  Summary of Doxorubicin effect on stroke volume compared to control   
in each phenotype.  * p < 0.05 vs. control value at each time point.  $ p < 0.05 vs. HCR 
phenotype at the same time point. 
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In contrast to the stroke volume changes, reciprocal patterns were seen in the heart 
rate responses.  The HCR animals tended to have increased heart rates in response to 
doxorubicin treatment, while the LCRS tended to show decreasing rate patterns.  The 
increased heart rates in the HCRs were significantly increased throughout the treatment 
period, while the decrease in hear rate in the LCRs abated within 7 days after treatment 
began (Table 13, Figures 24, 25).   
 
TABLE 13. Summary of heart rate (Rate) changes caused by doxorubicin treatment in each 
phenotype. 
 
    Rate (bpm)   
  day 0 day 1 day 4 day 7  day 10 
HCR + DOX 374 336 343 376 352 
 
393 326 381 380 340 
 
307 326 381 370 333 
 
345 386 421 377 377 
  357 370 532 301 366 
mean 355 349 412 361 354 
SEM 15 12 33 15 8 
p vs day 0 
 
0.3821 0.0377 0.1689 0.3645 
p vs HCR 0.0399 0.0811 0.0005 0.0190 0.0314 
      
LCR + DOX 337 277 295 344 336 
 
306 308 308 309 332 
 
296 311 276 320 324 
 
375 315 314 369 332 
 
245 262 327 358 305 
 
338 439 328 336 337 
 
353 317 349 353 345 
 315 242 23 285 318 
mean 321 309 278 334 329 
SEM 14 21 37 10 4 
p vs day 0 
 
0.2921 0.1834 0.0514 0.2971 
p vs LCR 0.1455 0.0495 0.0059 0.4858 0.2981 
p vs. HCR D  0.0663 0.0954 0.0152 0.0754 0.0066 
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Figure  24.  Summary of left ventricular end-systolic volume (LVESV) changes caused by 
doxorubicin treatment in each phenotype. 
 
Figure 25. Summary of Doxorubicin effect on heart rate compared to control   
in each phenotype.  * p < 0.05 vs. control value at each time point.  $ p < 0.05 vs. HCR 
phenotype at the same time point. 
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Cardiac output is the product of heart rate and stroke volume.  The aggregate effects 
of doxorubicin treatment on the HCRs were an increase in total output that was significant 
by Day 7 after treatment.  In LCR animals, doxorubicin treatment tended to increase output 
early after treatment, but only weakly so, and cardiac output was consistently reduced 
compared to the HCR animals (Table 14, Figures 26, 27). 
TABLE 14. Summary of cardiac output (CO) changes caused by doxorubicin treatment in each 
phenotype. 
 
    CO (ul/min/g)     
 day 0 day 1 day4 day 7  day 10 
HCR + DOX 107.33 199.23 245.54 151.66 284.49 
 
298.03 132.70 260.23 68.01 219.68 
 
113.72 200.78 178.05 224.36 196.60 
 
255.76 238.34 275.73 218.54 283.59 
  108.30 182.65 196.04 189.25 107.76 
mean 177 191 231 170 218 
SEM 41 17 19 29 33 
p vs day 0 
 
0.3940 0.0898 0.1039 0.1735 
p vs HCR 0.0830 0.1100 0.4459 0.0496 0.3271 
      
LCR + DOX 153 106 168 157 212 
 
121 125 196 87 157 
 
147 134 130 100 161 
 
223 190 214 216 191 
 
91 104 139 140 143 
 
103 86 161 144 102 
 
119 123 79 166 105 
 163 105 109 152 184 
mean 140 122 150 145 157 
SEM 15 11 16 14 14 
p vs day 0 
 
0.0420 0.0498 0.4227 0.2679 
p vs LCR 0.2656 0.2222 0.0984 0.1492 0.0308 
p vs. HCR D 0.1718 0.0023 0.0037 0.2002 0.0358 
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Figure 26.   Summary of left ventricular cardiac output (CO) changes caused by doxorubicin 
treatment in each phenotype. 
 
Figure 27.  Summary of Doxorubicin effect on cardiac output compared to control   
in each phenotype.  * p < 0.05 vs. control value at each time point.  $ p < 0.05 vs. HCR 
phenotype at the same time point. 
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Ejection fraction decreased at all times in the HCR animals following treatment with 
doxorubicin, consistent with a decrease in contractility, but did not change at any time after 
treatment in the LCRs.  The differences in response to doxorubicin treatment remained 
significant throughout the first week, but had normalized by ten days (Table 15, Figures 28, 
29).   
TABLE 15. Summary of left ventricular ejection fraction (LV EF) changes caused by 
doxorubicin treatment in each phenotype. 
 
    LV EF (%)     
  day 0 day 1 day 4 day 7  day 10 
HCR + DOX 70 67 70 64 64 
 
75 54 66 56 72 
 
51 65 59 74 60 
 
54 61 48 56 47 
  73 59 70 64 65 
mean 65 61 63 63 62 
SEM 5 2 4 3 4 
p vs day 0 
 
0.3111 0.3863 0.4997 0.4164 
p vs HCR 0.0189 0.0000 0.0016 0.0004 0.0006 
      
LCR + DOX 85 68 75 82 87 
 
72 77 63 74 64 
 
93 77 77 58 66 
 
89 75 77 67 63 
 
75 77 73 72 66 
 
71 69 80 72 71 
 
82 85 60 81 79 
 83 64 76 90 82 
mean 81 74 72 74 72 
SEM 3 2 3 3 3 
p vs day 0 
 
0.0418 0.3837 0.3510 0.1866 
p vs LCR 0.0010 0.3531 0.4151 0.3024 0.3933 
p vs. HCR D 0.0054 0.0023 0.0286 0.0226 0.0345 
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Figure 28.  Summary of left ventricular ejection fraction (LV EF) changes caused by 
doxorubicin treatment in each phenotype.  $ p < 0.05 vs. HCR phenotype at the same time 
point. 
 
Figure 29.   Summary of Doxorubicin effect on ejection fraction compared to control   
in each phenotype.  * p < 0.05 vs. control value at each time point.  $ p < 0.05 vs. HCR 
phenotype at the same time point. 
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Mitochodrial Respiratory Capacity 
Increases in oxygen consumption above baseline were seen with the addition of ADP, 
and with subsequent addition of succinate in the glutamate malate protocol.  Values for 
oxygen consumption are consistent with those reported in isolated fibers from young rat, 
and there were no differences between the phenotypes, suggesting that there was no age 
dependent decrement in cardiac mitochondrial function, and no impact of phenoptype on 
that outcome.  (Table 16, Figure 30). 
TABLE 16.  Summary of oxygen consumption data under Glutamate/Malate protocol 
conditions, obtained using cardiac mitochondria isolated from aged HCR and LCR animals. 
 
    Condition     
Group baseline G/M ADP SUCC ROT FCCP 
HCR 377.9 528.9 860.0 1516.2 1016.7 991.6 
 
12.6 50.9 290.1 545.2 334.6 289.7 
 78.8 96.0 159.6 229.9 198.9 192.2 
mean 156.4 225.3 436.6 763.8 516.7 491.2 
SEM 112.4 152.4 215.0 387.1 253.0 251.8 
p vs. Baseline 
 
0.3633 0.0466 0.0112 0.0270 0.0354 
p vs. Previous    0.0573 0.0995 0.1060 0.0733 
       LCR 379.7 636.5 790.9 1064.1 896.9 960.0 
 
103.3 118.0 418.7 787.1 430.7 441.9 
 
128.1 178.7 527.1 759.2 427.9 425.2 
 
232.4 284.0 711.5 1002.2 579.8 527.1 
 
231.3 249.5 503.9 729.8 423.8 390.8 
 126.6 175.6 418.5 664.9 456.5 399.9 
mean 200.2 273.7 561.8 834.5 535.9 524.2 
SEM 42.5 76.4 63.4 65.4 76.1 89.4 
p vs Baseline 
 
0.1490 0.0001 0.0000 0.0004 0.0011 
p vs. Previous    0.0003 0.0000 0.0003 0.2773 
p vs HCR 0.3715 0.3972 0.3125 0.4364 0.4739 0.4555 
Baseline; oxygen consumption with only mitochondria and buffer; G/M, oxygen 
consumption with subsequent addition of Glutamate /malate; ADP, oxygen consumption 
with subsequent addition of ADP; SUCC, oxygen consumption with subsequent addition of 
succinate; ROT, oxygen consumption with subsequent addition of Rotenone; FCCP, oxygen 
consumption with subsequent addition of carbonylcyanide-p-
trifluoromethoxyphenylhydrazone 
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Figure 30.  Comparison of phenotype effects on aging dependent changes in cardiac 
mitochondrial function, measured as oxygen consumption, under different substrate 
conditions in a glutamate based protocol.   G/M, glutamate malate; ADP, adenosine 
diphosphate; SUCC, succinate; ROT, Rotenone; FCCP,  carbonylcyanide-p-
trifluoromethoxyphenylhydrazone.  * indicates p<0.05 vs. baseline value for the phenotype; 
# indicates p< 0.05 vs. previous treatment condition for the phenotype. 
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Progressive, stepwise increases in oxygen consumption above baseline were seen 
with the addition of ADP, and with subsequent addition of glutamate and then succinate in 
the plamitoyl carnitine (fatty acid) protocol.  As in the previous protocol, values for oxygen 
consumption are consistent with those reported in isolated fibers from young rat, and there 
were no differences between the phenotypes, suggesting that there was no age dependent 
decrement in cardiac mitochondrial function, and no impact of phenoptype on that 
outcome.  (Table 17, Figure 31). 
TABLE 17.   Summary of oxygen consumption data under Palmitate/Malate (Fatty Acid) 
protocol conditions, obtained using cardiac mitochondria isolated from aged HCR and LCR 
animals. 
 
    Condition     
Group Baseline M/PC ADP GLUT SUCC FCCP 
HCR 411.4 580.8 1871.3 2493.3 3036.7 2657.5 
 
10.7 71.6 615.6 852.8 1099.0 835.2 
 
96.4 107.6 180.2 249.2 301.5 318.2 
mean 172.9 253.4 889.0 1198.5 1479.1 1270.3 
SEM 121.8 164.1 506.9 670.5 812.1 709.5 
  
0.2941 0.0145 0.0088 0.0065 0.0082 
 
   0.1074 0.0996 0.0942 0.1088 
       LCR 437.8 611.2 1019.0 980.1 1381.9 1186.1 
 
123.9 141.1 483.5 811.2 1036.0 856.1 
 
134.1 156.4 543.9 837.5 1009.7 936.7 
 
233.9 287.7 795.1 1058.9 1192.6 1206.4 
 
59.2 237.3 555.6 954.2 1104.9 994.2 
 
153.5 198.2 464.7 729.1 879.9 874.7 
mean 190.4 272.0 643.6 895.1 1100.8 1009.0 
SEM 54.5 71.3 89.3 50.1 70.4 62.5 
p vs. baseline 
 
0.1588 0.0002 0.0000 0.0000 0.0000 
p vs. previous    0.0001 0.0048 0.0021 0.0247 
p vs. HCR 0.4521 0.4621 0.3391 0.2587 0.3438 0.3742 
Baseline; oxygen consumption with only mitochondria and buffer; M/P, oxygen 
consumption with subsequent addition of malate/palmitoyl carnitine; ADP, oxygen 
consumption with subsequent addition of ADP; GLUT, oxygen consumption with subsequent 
addition of glutamate; SUCC, oxygen consumption with subsequent addition of succinate; 
FCCP, oxygen consumption with subsequent addition of  carbonylcyanide-p-
trifluoromethoxyphenylhydrazone 
  56 
 
 
 
 
 
 
 
Figure 31. Comparison of phenotype effects on aging dependent changes in cardiac 
mitochondrial function, measured as oxygen consumption, under different substrate 
conditions in a fatty acid based protocol.   M/PC, malate/ palmitoyl carntiine; ADP, 
adenosine diphosphate; GLUT, glutamate; SUCC, succinate;  FCCP, carbonylcyanide-p-
trifluoromethoxyphenylhydrazone.  * indicates p<0.05 vs. baseline value for the Comparison 
of phenotype effects on aging dependent changes in mitochondrial function is a glucose 
based protocol.  * indicates p<0.05 vs. baseline value for the phenotype; # indicates p< 0.05 
vs. previous treatment condition for the phenotype. 
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Doxorubicin treatment caused a significant increase in the oxygen consumption of 
cardiac mitochondria isolated from LCR animals stimulated with glutamate malate, ADP, and 
succinate, but not in mitochondira isolated from HCR animals (Table 18, Figure 32).    In 
contrast, doxorubicin treatment did not produce phenotype specific differences in 
mitochondrial oxygen consumption when stimulated with the fatty acid based protocol 
(Table 19, Figure 33).     
When compared to the control responses, doxorubicin increased mitochondrial 
respiratory capacity 2-5 fold in LCRs in the glutamate protocol, but HCR isolates did not 
increased respiratory capacity in response Doxorubicin treatment in any substrate protocol 
(Figures 34 and 35).      
The doxorubicin induced increase in respiratory capacity may have been a 
compensation for a decrease in total mitochondrial number, as mitochondrial protein was 
approximately 30% higher (p = 0.061) in the HCR animals under all conditions tested (Figure 
36).    Doxorubicin did not cause a decrease in mitochondrial protein content, but the 
baseline differences between LCRs and HCRs may have required an inducible adaptation in 
the LCRs at the mitochondrial level to respond to the increased stress placed on the system 
by doxorubicin treatment.     
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TABLE 18.  Summary of oxygen consumption data under Glucose/Malate protocol 
conditions, obtained using cardiac mitochondria isolated from aged HCR and LCR animals 10 
days after doxorubicin treatment. 
 
    Condition     
Group baseline G/M ADP SUCC ROT FCCP 
HCR + Dox 249.9 332.7 658.7 1160.4 744.0 737.6 
 
339.7 500.1 609.1 901.3 747.1 801.3 
 
97.7 122.8 527.2 1066.8 574.4 533.1 
 
125.1 113.2 500.3 874.1 496.2 423.9 
 65.1 90.6 362.2 568.5 292.8 267.8 
mean 175.5 231.9 531.5 914.2 570.9 552.7 
SEM 51.6 80.0 50.9 101.3 84.8 98.5 
p vs Baseline 
 
0.0671 0.0002 0.0007 0.0006 0.0011 
p vs. Previous    0.0024 0.0018 0.0021 0.2187 
       LCR + Dox 389.9 519.3 580.2 754.1 665.8 693.9 
  
223.2 1086.1 1733.3 1227.6 1160.1 
 
108.5 242.6 1386.6 2796.7 1242.3 1195.7 
 
80.5 101.6 135.9 234.7 197.7 181.1 
 
103.0 137.1 342.8 569.6 378.4 389.3 
 
1030.1 1371.0 3427.9 5695.5 3783.8 3893.1 
 
2565.4 3017.1 5286.2 7710.9 5296.6 4873.9 
 530.1 1777.1 7069.1 9750.5 4527.0 4193.2 
mean 686.8 923.6 2414.4 3655.6 2164.9 2072.5 
SEM 316.3 371.4 912.3 1280.6 720.2 675.8 
p vs Baseline 
 
0.0422 0.0351 0.0213 0.0163 0.0154 
p vs. Previous    0.0239 0.0074 0.0239 0.1013 
p vs HCR 0.1193 0.0539 0.0390 0.0349 0.0314 0.0299 
 
Baseline; oxygen consumption with only mitochondria and buffer; G/M, oxygen 
consumption with subsequent addition of Glutamate/malate; ADP, oxygen consumption 
with subsequent addition of ADP; SUCC, oxygen consumption with subsequent addition of 
succinate; ROT, oxygen consumption with subsequent addition of Rotenone; FCCP, oxygen 
consumption with subsequent addition of carbonylcyanide-p-
trifluoromethoxyphenylhydrazone 
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TABLE 19.  Summary of oxygen consumption data under Palmitate/Malate (Fatty Acid) 
protocol conditions, obtained using cardiac mitochondria isolated from aged HCR and LCR 
animals 10 days after doxorubicin treatment. 
 
    Condition     
Group Baseline M/PC ADP GLUT SUCC FCCP 
HCR + DOX 227.9 323.4 870.2 1326.6 1632.8 1282.7 
 
403.3 561.4 987.9 978.5 1350.9 1169.2 
 
99.5 155.9 768.5 1158.4 1437.3 1014.9 
 
114.5 124.2 514.8 994.4 1287.6 1009.9 
 
340.0 340.0 340.0 340.0 340.0 340.0 
mean 237.0 301.0 696.3 959.6 1209.7 963.3 
SEM 60.1 78.1 118.4 167.3 225.1 164.0 
p vs. baseline 
 
0.0465 0.0104 0.0118 0.0095 0.0089 
p vs. previous    0.0104 0.0378 0.0090 0.0142 
       LCR + DOX 435.6 594.4 817.4 903.5 1040.1 981.3 
 
9.3 304.1 1865.5 2579.6 3172.2 1809.1 
 
94.9 316.1 399.6 1481.1 2808.9 1487.0 
 
108.0 101.6 183.5 235.2 287.6 295.9 
 
146.4 178.0 591.6 919.9 1130.6 837.8 
 
283.6 344.9 654.1 901.7 1104.0 1040.7 
 
51.7 208.8 746.5 1229.9 1387.0 1235.1 
 150.5 166.3 289.4 354.5 428.1 422.0 
mean 160.0 276.8 693.4 1075.7 1419.8 1013.6 
SEM 48.7 54.3 184.8 259.1 368.3 179.5 
p vs. baseline 
 
0.0092 0.0162 0.0071 0.0073 0.0018 
p vs. previous    0.0236 0.0104 0.0294 0.0453 
p vs. HCR 0.1730 0.4029 0.4950 0.3570 0.3181 0.4201 
Baseline; oxygen consumption with only mitochondria and buffer; M/P, oxygen 
consumption with subsequent addition of malate/palmitoyl carnitine; ADP, oxygen 
consumption with subsequent addition of ADP; GLUT, oxygen consumption with subsequent 
addition of glutamate; SUCC, oxygen consumption with subsequent addition of succinate; 
FCCP, oxygen consumption with subsequent addition of carbonylcyanide-p-
trifluoromethoxyphenylhydrazone 
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Figure 32.  Comparison of phenotype influence on doxorubicin dependent changes in 
cardiac mitochondrial function, measured as oxygen consumption, under different 
substrate conditions in a glutamate based protocol.   G/M, glutamate malate; ADP, 
adenosine diphosphate; SUCC, succinate; ROT, Rotenone; FCCP, carbonylcyanide-p-
trifluoromethoxyphenylhydrazone .  * indicates p<0.05 vs. baseline value for the phenotype; 
# indicates p< 0.05 vs. previous treatment condition for the phenotype; $ indicates p<0.05 
vs. HCR value under the same conditions. 
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Figure 33.  Comparison of phenotype influence on doxorubicin dependent changes in 
cardiac mitochondrial function, measured as oxygen consumption, under different 
substrate conditions in a fatty acid based protocol.   M/PC, malate/ palmitoyl carntiine; 
ADP, adenosine diphosphate; GLUT, glutamate; SUCC, succinate;  FCCP, carbonylcyanide-p-
trifluoromethoxyphenylhydrazone.  * indicates p<0.05 vs. baseline value for the Comparison 
of phenotype effects on aging dependent changes in mitochondrial function is a glucose 
based protocol.  * indicates p<0.05 vs. baseline value for the phenotype; # indicates p< 0.05 
vs. previous treatment condition for the phenotype. 
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Figure 34.  Comparison of doxorubicin effects on cardiac mitochondrial function, measured 
as oxygen consumption, under different substrate conditions in a glutamate based 
protocol.   G/M, glutamate malate; ADP, adenosine diphosphate; SUCC, succinate; ROT, 
Rotenone; FCCP,. carbonylcyanide-p-trifluoromethoxyphenylhydrazone  * indicates p<0.05 
vs. baseline value for the phenotype; # indicates p< 0.05 vs. previous treatment condition for 
the phenotype; $ indicates p<0.05 vs. HCR value under the same conditions. 
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Figure 35.  Comparison of doxorubicin effects on cardiac mitochondrial function, measured 
as oxygen consumption, under different substrate conditions in a fatty acid based 
protocol.   M/PC, malate/ palmitoyl carntiine; ADP, adenosine diphosphate; GLUT, 
glutamate; SUCC, succinate;  FCCP, carbonylcyanide-p-trifluoromethoxyphenylhydrazone .  * 
indicates p<0.05 vs. baseline value for the Comparison of phenotype effects on aging 
dependent changes in mitochondrial function is a glucose based protocol.  * indicates p<0.05 
vs. baseline value for the phenotype; # indicates p< 0.05 vs. previous treatment condition for 
the phenotype. 
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Figure 36.  Comparison of mitochondrial protein amounts in control and doxorubicin 
treated animals.   Doxorubicin did not cause a loss in mitochondrial protein in either 
phenotype, but HCRs consistently demonstrated 30-35% higher mitochondrial protein 
content per unit LV mass than the LCRs. 
CHAPTER IV: DISCUSSION 
Aerobic exercise capacity influences quality of life and has been shown to be 
powerful predictor of mortality (Koch et al., 2008). The protective effects of active aerobic 
capacity, as studied through exercise preconditioning training, have been well described as 
improving myocardial tolerance to harmful oxidative stress (Ascensao et al., 2012). However, 
the role of innate aerobic capacity, versus active exercise training, is largely unexplored. 
Therefore, the goal of this study was to examine the effect of inherent differences in aerobic 
capacity in response to Doxorubicin-induced toxicity. As HCRs demonstrate lower 
cardiovascular risk factors, we wanted to test specifically whether HCRs were less susceptible 
to doxorubicin-induced cardiotoxicity (Lujan et al. 2006). Our hypothesis was that the low 
aerobic running capacity (LCR) phenotype will show increased susceptibility to the DOX-
induced cardiotoxicity when compared to the high aerobic running capacity (HCR) 
phenotype.  In this study, it was hypothesized that impairment of mitochondrial function and 
cardiac performance may link reduced fitness from doxorubicin-induced cardiotoxicity. The 
results indicate that our hypothesis was oversimplified, as the mitochondrial function and 
cardiac performance responses to Doxorubicin varied with the divergent phenotypes.   
In order to focus on the role of cardiac dysfunction after doxorubicin treatment in 
aging aerobic capacity phenotypes, we studied two strains of rat presenting the divergent 
phenotypes: the HCR and LCR rats. The control animals that were not treated with 
doxorubicin did not perform significantly different in either test, suggesting that aging 
reduced the phenotypic differences seen in younger animal studies. We expected that the 
HCR rats would outperform the LCR animals, which corresponds with other rat strain studies, 
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in which the rats with the longest life spans are less affected by age-related pathology and 
show completely normal mitochondrial function in the elderly (Lemieux et al., 2010). 
Interestingly, possibly due to a husbandry effect, our LCR animals outlived the HCR animals 
when considering spontaneous mortality. However, given insignificant differences between 
our control animal phenotypes in mitochondrial function and cardiac performance, it is 
difficult to dispel any of the uncertainty in the role that aging plays in attenuating the 
intrinsic benefits of a high aerobic capacity. This suggests that as one ages, the benefit of an 
innate high aerobic capacity may reduce with age. A possible explanation to the demise of 
this benefit is that oxidative damage to the mitochondrial DNA and electron transport chain 
accumulates with age. This reduces mitochondrial energetic capacity, further stimulating 
oxygen free radical production. The resulting mitochondrial DNA damage inhibits 
mitochondrial biogenesis and increases replication errors and mitochondrial DNA deletions, 
thus creating a vicious circle. Doxorubicin treatment in conjunction with an aged phenotype 
is therefore an ideal situation for these events to occur, as oxygen free radicals are produced 
and mitochondrial DNA deletion takes place. Cardiac failure as a result of Dox administration 
is attributed to increased reactive oxygen species (ROS) production by the mitochondria. 
Specifically, it has been proposed that Dox stimulates ROS through mitochondrial NADH 
dehydrogenase, leading to the generation of a free radical cascade with a potent oxidizing 
potential. However, one study reported lower oxidative DNA mutations despite greater 
reactive oxygen species in skeletal muscles from HCR rats (Tweedie et al, 2011). Therefore, 
the phenotypic benefit of a high aerobic capacity may have disappeared due to an altered 
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mitochondrial biogenesis from the preexisting excessive amounts of oxidative damage due 
to aging (Alexeyev et al., 2004; Alexeyev et al., 2009).  
Furthermore, it is expected that if the dosage and consequently, the concentration of 
the doxorubicin was higher, the inhibition of both fatty acids and glucose oxidation would 
have been seen (Abdel-aleem et al., 1997).  Following doxorubicin treatment, the LCR 
animals exhibited elevated levels of mitochondrial respiration, especially in the glutamate-
based protocol. Also, the LCR animals responded by increasing their cardiac volumes but did 
not succeed in increasing their cardiac output, while the HCRs increased their heart rate and 
cardiac output, albeit in the total absence of exercise training. Taken together, these data 
demonstrate that intrinsic aerobic capacity influences the adaptive responses following DOX-
injury and perhaps the progression of DOX-induced cardiotoxicity. 
Similarly to the effects of endurance exercise, the possibility exists that HCRs have 
improvements in innate myocardial antioxidant capacity which contribute protection against 
the doxorubicin-induced damage (Quindry et al., 2005). Inversely, LCR rat hearts may be 
vulnerable to doxorubicin cardiotoxicity due to limited antioxidant mechanisms that could 
protect them from oxidative stress (Ashour et al., 2012). However, antioxidants are not 
cardiac specific and therefore reduce oxidative stress nonspecifically (Oliveira et al., 2011). 
Thus, the results from the present investigation provide novel insight into potential 
mechanisms associated with cardiovascular failure in a system that allows for each strain to 
serve as a control for unknown environmental changes (Rivas et al., 2011).  
As one ages, mitochondrial mutations accumulate causing mitochondrial dysfunction 
and a decline in antioxidant capacity, which correlate with aerobic capacity. A mitochondrial 
  68 
 
defect associated with aging has involved a decrease in complex III and IV activities (Fannin 
et al., 1999; Moghaddas et al., 2002; Lesnefsky et al., 2006).The addition of the doxorubicin 
stress may accelerate these mutational processes and advance the decline of normal 
physiological functions. Moreover, there is a greater necessity of cardiac tissue to avoid 
mutational insult as cardiomyocytes are postreplicative and unable to repair the DNA 
damage. The progressive accumulation of mitochondrial mutations in affected hearts will 
increase the severity of the organ phenotype damage associated with those mutations 
(Stevenson et al., 2006). This lack of regeneration capability in conjunction with 
cardiomyocyte damage could explain the deterioration of cardiac function (L’Ecuyer et al., 
2006). Reactive oxygen species cause injury to mitochondrial transcription that exacerbates 
mitochondrial dysfunction by inhibiting synthesis of respiratory chain proteins (Tang et al., 
2002). The proximity of the ETC to the relatively unprotected mitochondrial DNA makes 
mitochondrial transcription proteins particularly vulnerable to oxidative stress (Kristal et al., 
1994). Complex I is the largest ETS complex and seven of its 40 constituent proteins are 
encoded by mitochondrial DNA whereas all 4 proteins of Complex II are encoded strictly by 
nuclear DNA. Thus, one hypothesis to explain the decreased activity of Complex I could be 
due to oxidative damage of mitochondrial DNA (Tang et al., 2002). Damaged mitochondria 
due to oxidative stress are a serious hazard to cardiac health and performance.  
Cardiac efficiency is the ratio between energy output (work) and energy input 
(myocardial oxygen consumption) for the heart. An increase in cardiac work is consistent 
with more efficient oxygen utilization by the heart to produce ATP and in turn, mechanical 
work (McCormack et al., 1998).  The evaluation of mitochondrial function is critical to 
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explore how doxorubicin affects cardiac performance as the organelle supplies 
cardiomyocytes with ATP, a crucial energy source for muscle contraction. Doxorubicin has 
been shown to cause a significant decrease in ATP (Ashour et al., 2012). Thus, a depressed 
mitochondrial function leads to a reduced work capacity, which is demonstrated as a 
lowered cardiac performance as evident through cardiac output. For this reason, we 
investigated the mitochondrial respiration properties of cardiac mitochondria from the 
LCR/HCR animals. 
Our study identifies change in mitochondrial function with doxorubicin treatment in 
isolated cardiac mitochondria that varies between the rat strains. Measurements of oxygen 
consumption provide an appropriate indication of mitochondrial function. Respirometry 
studies were performed to determine inefficient cardiac mitochondrial function, which is 
known to lead to added oxidant stress levels and may therefore play a direct role in the 
reduction of cardiac performance (Stevenson et al., 2006). The addition of different 
substrates and analysis of electron flow from the complexes of the ETC is used to determine 
the functional activity of the ETC and allows for the identification of a specific impaired 
complex. In the glutamate-based protocol, the sequential injections of glutamate and malate 
were used to determine the effect of these substrates on mitochondrial respiration when 
electrons are provided to complex I. A further injection of succinate was used to assess the 
effect of electron input through complex I and complex II. Rotenone was added to 
specifically inhibit complex I, thereby allowing the evaluation of mitochondrial respiration 
through only complex II. The analysis of beta-oxidation metabolism substrates were analyzed 
using the palmitoyl-carnitine based respiration protocol. In muscles, mitochondrial fatty acid 
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beta-oxidation provides acetyl-CoA into the Krebs cycle for production of ATP. When 
supported with beta-oxidation, there was not a significant difference in the response, but 
generally DOX-treated HCR rats exhibited depressed oxygen consumption levels and the 
LCRs increased in oxygen consumption.  
There are several explanations for the differences exhibited in the LCR and HCR 
responses to Doxorubicin treatment. The first explanation is that because of their genetic 
endowment, the HCR rats have less need to adapt to the doxorubicin injury than the LCR 
rats. The HCRs may have been intrinsically prepared to handle the doxorubicin insult. Thus, 
the lack of a mitochondrial respiration response by the HCR animals to the drug may be 
because the stress was not as impactful for that phenotype in comparison to the LCRs. 
Supporting evidence for such a postulate can be seen in our oxygen consumption data; the 
LCR rats increased their oxygen consumption after doxorubicin treatment while the HCR rats 
exhibited relatively stable rates. Moreover, after doxorubicin treatment, the HCRs 
responded by increasing their heart rate, while the LCRs increased their volumes. This 
supports the explanation that this same experimental drug treatment induced a different 
injury within the phenotypes due to the genetic endowment. Although both phenotypes 
were given similar dosages, it is likely that the HCRs are endowed with inherent advantages 
that make them better equipped to tolerate the doxorubicin cardiac insult and therefore did 
not need to recover like the LCRs. One innate advantage of the HCRS may be a higher 
mitochondrial density.  
As previously reported, doxorubicin is associated with several signs of 
cardiomyopathy: LV hypertrophy, changes in ventricle diameter, cardiomyocytes 
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hypertrophy and loss, fibrosis and collagen deposition (Lemieux et al., 2010; Schwartz et al., 
1998). These findings are consistent with our observation that DOX-treated LCR hearts have 
increased geometric dimensions and stroke volume, but a depressed cardiac output, which 
may reflect a compensatory remodeling response to the doxorubicin toxicity in the heart. 
The correspondence between DOX-treated LCRs and models of cardiomyopathy is testament 
to the importance of low aerobic capacity in the development of cardiac failure. Our 
investigation supports the thesis that in aged populations, depressed aerobic capacity is the 
antecedent of cardiac dysfunction.  
Other characteristics of the animal model may have played a role in the divergent 
response to Doxorubicin. The LCR animals’ characteristic large adiposity could have been a 
factor in doxorubicin’s cardiotoxicity as it is recognized that the drug does not achieve high 
concentrations in fat tissue and that obesity has been shown to slow the metabolism of the 
drug. Therefore, it is hypothesized that since anthracyclines do not distribute into fat then 
equivalent doses based on body surface area may lead to higher concentrations of 
doxorubicin in the hearts of LCRs than HCRs (Silber et al., 1993). Moreover, it is well studied 
that LCR rats become exhausted more quickly, run for shorter distances and at slower paces 
compared to HCR rats (Buck et al., 2012). Interestingly, it has also been found that there is a 
sex effect with females having higher numbers of functional mitochondria than males 
(Demarco et al., 2012). HCR rats have been shown to have higher markers of mitochondrial 
content in their locomotor muscles (Tweedie et al., 2011). HCRs have been found to have 
superior mitochondrial content in skeletal muscle. Increased body weight, decreased fatty 
acid oxidation, and reduced insulin sensitivity has been associated with the reduced 
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mitochondrial content in the skeletal muscle of LCR rats (Rivas et al., 2011). A determinant of 
aerobic capacity performance is local oxidative capacity, namely, mitochondrial density. To 
achieve a given rate of oxygen uptake, greater mitochondrial density will require a lesser 
degree of activation per mitochondrion. Subsequently, smaller increases in controllers of 
respiration, such as ADP (Walsh et al., 2006). Due of these inherent advantages, it is likely 
that doxorubicin produced less insult in the HCR rats than the LCRs, and consequently 
induced less observable changes in mitochondrial respiration. Taken together, there is a 
strong argument that the differences between the phenotypes in their adaptive responses to 
doxorubicin is determined by the inherent differences that exist due to the genetic 
endowment.  
A second possible explanation for the differences in response to DOX between the 
phenotypes is that the two groups adapt similarly, but the LCR response is attenuated due to 
poor intrinsic aerobic capacity. In the cardiac performance data, we see that the LCR animals’ 
cardiac output is initially decreased, but by the fourteenth day, the LCRs demonstrated 
increases in this value to similar levels as the HCRs. These data support the explanation that 
the adaptive responses employed by the HCR and LCR animals are similar but the timing of 
the response is the component that is influenced by inherent aerobic exercise capacity. 
However, one item to take into consideration is that the dosage of doxorubicin may be 
affecting the animals in a bimodal manner. It is possible that the dosage of doxorubicin may 
have caused a two-waved systemic response, and a larger dosage may have produced a 
more direct cardiotoxic effect. Therefore, the change in our cardiac performance responses 
throughout the 10 day study could be separated into the first initiatory stage where local 
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reactions were activated, and days later, a secondary release of effects may have been 
induced. This secondary wave may be responsible for the wide range of systemic effects 
(Ceciliani et al., 2002). Many factors are involved in the initiation and progression of 
doxorubicin cardiotoxicity and the finding that the drug response may be bimodal is an 
important technical consideration for anyone involved in the studies in this model, in 
particular with regard to the interpretation of findings (Wapstra, et al., 1999).    
Though our specific doxorubicin dose has been extensively used as a treatment in 
rats, it is likely that different doses of doxorubicin induce effects that vary considerably 
among investigators. Under the experimental conditions of our laboratory, in the aged rat 
strains, our single intraperitoneal 7.5mg/kg doxorubicin dose appeared to be the most 
appropriate dose. However, our study results may have also varied if we sacrificed the 
animals earlier (such as day 4 or day 7) and examined mitochondrial function sooner. We 
may have seen a more pronounced difference in the cardiac mitochondrial function between 
the phenotypes. Based on our results, we most likely examined acute doxorubicin 
cardiotoxicity, which are nonlifethreatening events that are resolved within a week. Acute 
cardiotoxicity damage resolves promptly to the cessation of doxorubicin infusion and rarely 
precludes further continuation of treatment. However, the types of chronic toxicity are 
irreversible and clinically significant, substantially affecting overall morbidity and mortality 
and requiring long-term therapy (Dazzi, et al., 2001). Studies have shown that the genetic 
makeup of patients may modulate the individual risk to develop cardiotoxicity (Deng et al., 
2007; Wojnowski et al., 2005). Thus, in experimental toxicity induced by doxorubicin, the 
dose of DOX used is crucial as it appears to be an important determinant not only of the 
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severity of the cardiotoxicity that eventually ensues, but notably of the responsiveness of the 
HCR and LCR animals.  
A third possible explanation is that the animal phenotypes utilize different 
mechanisms to adapt to the doxorubicin treatment. This conclusion is supported by the 
cardiac performance results that show that the HCR rats changed heart rate but the LCR rats 
did not. Furthermore, the LCR phenotype adapted to DOX by increasing the volumes, but the 
HCR rats did not demonstrate this change. These data support the explanation that 
difference in adaptive response to doxorubicin may be due to different mechanism and 
pathways. We also showed that doxorubicin induced an adaptation of the mitochondria in 
LCRs whereby the glutamate-based oxygen consumption increased. As discussed earlier, if 
the doxorubicin dose is mild, a low aerobic capacity phenotype induces an adaptive 
mitochondrial respiration and increased volumes. The HCR animals did not exhibit a change 
in mitochondrial respiration but doxorubicin did induce an elevated heart rate which 
transpired into an increased cardiac output. In contrast, it is theorized that a more severe 
dosage results in an accumulation of doxorubicin in mitochondria that subsequently leads to 
heart failure. Thus, these results suggest that the beneficial effects of a high aerobic capacity 
phenotype encompass unique protective mechanisms to cardiotoxicity, guiding to an 
improved mitochondrial and cardiac function, and thereby, to a higher fitness. Hence, 
intrinsic aerobic capacity may respond to the same stressor with different mechanistic 
adaptive responses determined in part by the same gene profiles that establish intrinsic 
aerobic running capacity.  
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The present study has established that intrinsic aerobic capacity influences adaptive 
cardiac responses to doxorubicin insult. The high intrinsic aerobic capacity phenotype 
responds by increasing heart rate and cardiac output within ten days. However, this 
phenotype makes no significant changes in mitochondrial respiration.  Therefore, it may be 
suggested that this phenotype utilizes a tachycardiac response to the doxorubicin treatment. 
This increase in cardiac output may be possible due to the HCR animals 25% greater amount 
of mitochondrial density.  
In conclusion, this study provides new insight into the effects of doxorubicin 
treatment on mitochondrial and cardiac function in rats with divergent aerobic capacities. 
Our investigation demonstrates that selection for the trait of low intrinsic aerobic capacity 
diminishes the performance of cardiac muscle in response to doxorubicin treatment. After 
drug infusion, the impaired cardiac output in animals bred for inferior aerobic capacity was 
associated with elevated cardiac volume dimensions and elevated mitochondrial respiration, 
particularly in the glutamate-based protocol. Furthermore, selection for high aerobic 
capacity, in the absence of exercise training, endows increased mitochondrial density, heart 
rate and cardiac output after doxorubicin treatment. These data provide some novel 
evidence that differences in the mitochondrial function and cardiac performance may have a 
role in the divergence in aerobic capacity in the LCR/HCR model. This is in agreement with 
previous studies that have reported data suggesting that reduced mitochondrial function 
may be an inherited defect and leads to the progression of metabolic disease states and 
aging (Rivas et al., 2011).  
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There are abundant opportunities in the future to study doxorubicin, particularly 
because it is one of the most widely prescribed chemotherapeutic agents while the 
mechanism of action is largely unknown.  Although a number of mechanisms have been 
postulated to explain the pathogenesis of cardiotoxicity and its associated clinical 
manifestations, the precise details of the cellular and subcellular alterations remain to be 
elucidated. Because no single mechanism that could fully explain the development of the 
depressed cardiac/mitochondrial function has been identified, it is likely that the cause is 
multifactorial. In this regard, there has been a recent surge in experimental studies 
suggesting mitochondria may be intimately involved in the cardiotoxicity. Further 
investigation of whether there are differences in markers of cardiac mitochondrial capacity 
and density between phenotypes should be determined. Methods to verify mitochondrial 
content include analyzing maximal citrate synthase activity, expression of mitochondrial 
proteins through western blotting and quantifying by transmission electron microscopy. 
Potential future projects based on the insight gained from the current study should include 
direct measurements of oxidative stress using a GSH/GSSG assay or spectrofluorometric 
determination of hydrogen peroxide. Also, it has been suggested that differences in 
individual antioxidant defenses may hold the key to understanding doxorubicin 
susceptibility, but no studies have demonstrated a clear link or plausible mechanism for this 
deficiency. Therefore, those with high aerobic capacity are expected to have greater 
antioxidant defenses to deal with stresses, such as doxorubicin treatment (Stevenson et al., 
2006). More research needs to explore the impact that intrinsic aerobic capacity has on the 
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role of doxorubicin and investigate effective agents that block the detrimental cardiotoxic 
effects of doxorubicin while preserving antitumor activity. 
According to the American Cancer Society and the National Cancer Institute, the 
number of Americans living with cancer is estimated to increase by nearly a third to almost 
18 million by 2022 (Siegel et al., 2012). Of the cancer survivor populations, there are 
approximately 350,000 pediatric cancer survivors currently in the United States (Mariotto et 
al., 2009). As the trend of improved survival and population aging converge to produce an 
increasing group of cancer survivors, it is becoming more vital that patients not only survive 
through cancer therapies, but also live beyond their cancer treatment. The fact that the 
more potent the anticancer agents, the greater the toxicity to normal tissues leads to the use 
of only a fraction of the curable dose of a drug. This is especially true for the anticancer 
agent doxorubicin, which has notorious cardiotoxic effects. Therefore, it is vital that 
advances to effectively protect against doxorubicin’s cardiotoxicity are developed to prevent 
cancer survivors from forming chronic life-threatening conditions, such as heart failure 
secondary to this therapy.  
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